Cargando…

Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention

OBJECTIVE: In our present study, our objective was to appraise guidelines on antithrombotic therapy in atrial fibrillation post-percutaneous coronary intervention and to explore the differences in treatment practices for better informed decision-making. METHODS: We searched for English language guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yongqiang, Zhang, Gaoxing, Zhang, Zhengzhipeng, Zhang, Shaozhao, Liu, Menghui, Lin, Yifen, Huang, Yiquan, Zhong, Xiangbin, Zhuang, Xiaodong, Liao, Xinxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877875/
https://www.ncbi.nlm.nih.gov/pubmed/35342701
http://dx.doi.org/10.5334/gh.1104
_version_ 1784658522142670848
author Fan, Yongqiang
Zhang, Gaoxing
Zhang, Zhengzhipeng
Zhang, Shaozhao
Liu, Menghui
Lin, Yifen
Huang, Yiquan
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
author_facet Fan, Yongqiang
Zhang, Gaoxing
Zhang, Zhengzhipeng
Zhang, Shaozhao
Liu, Menghui
Lin, Yifen
Huang, Yiquan
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
author_sort Fan, Yongqiang
collection PubMed
description OBJECTIVE: In our present study, our objective was to appraise guidelines on antithrombotic therapy in atrial fibrillation post-percutaneous coronary intervention and to explore the differences in treatment practices for better informed decision-making. METHODS: We searched for English language guidelines published between January 2000 and December 2020 at MEDLINE, Embase and websites of guideline organizations. Guidelines with recommendations on antithrombotic regimens for patients with AF undergoing PCI were included. Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument was applied to assess guidelines. The reporting of conflicts of interest (COI) was evaluated separately by the RIGHT (Reporting Item for Practice Guidelines in Healthcare) checklist as supplementary items. RESULTS: Sixteen guidelines were included, among which 13 (81.25%) were considered as ‘recommended’ and 1 (6.25%) as ‘unrecommended.’ The average scores of guidelines ranged from 55% to 88% (<60% as low quality, 60–70% as sufficient quality, and >70% as good quality). Among the 6 domains of AGREE II, scope and purpose (84%) and editorial independence(87%) were considered to be the fields in which CPGs performed best, evidenced by the highest mean AGREE II scores. The domains in which the reviewed CPGs received the lowest mean scores were stakeholder involvement (63%) and applicability (58%). The intraclass correlation coefficient scores were excellent in each domain. The overall quality of the selected CPGs was optimal, with the highest score in domain ‘scope and purpose’, and the lowest score in the domain ‘applicability.’ The reporting of COI was satisfactory. CONCLUSIONS: For the recommendations on antithrombotic strategies, guidelines with high AGREE II scores still exist discrepancy on the timing and selection. Current guidance documents on the treatment vary in methodological rigor and recommendations are not always consistent.
format Online
Article
Text
id pubmed-8877875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-88778752022-03-24 Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention Fan, Yongqiang Zhang, Gaoxing Zhang, Zhengzhipeng Zhang, Shaozhao Liu, Menghui Lin, Yifen Huang, Yiquan Zhong, Xiangbin Zhuang, Xiaodong Liao, Xinxue Glob Heart Original Research OBJECTIVE: In our present study, our objective was to appraise guidelines on antithrombotic therapy in atrial fibrillation post-percutaneous coronary intervention and to explore the differences in treatment practices for better informed decision-making. METHODS: We searched for English language guidelines published between January 2000 and December 2020 at MEDLINE, Embase and websites of guideline organizations. Guidelines with recommendations on antithrombotic regimens for patients with AF undergoing PCI were included. Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument was applied to assess guidelines. The reporting of conflicts of interest (COI) was evaluated separately by the RIGHT (Reporting Item for Practice Guidelines in Healthcare) checklist as supplementary items. RESULTS: Sixteen guidelines were included, among which 13 (81.25%) were considered as ‘recommended’ and 1 (6.25%) as ‘unrecommended.’ The average scores of guidelines ranged from 55% to 88% (<60% as low quality, 60–70% as sufficient quality, and >70% as good quality). Among the 6 domains of AGREE II, scope and purpose (84%) and editorial independence(87%) were considered to be the fields in which CPGs performed best, evidenced by the highest mean AGREE II scores. The domains in which the reviewed CPGs received the lowest mean scores were stakeholder involvement (63%) and applicability (58%). The intraclass correlation coefficient scores were excellent in each domain. The overall quality of the selected CPGs was optimal, with the highest score in domain ‘scope and purpose’, and the lowest score in the domain ‘applicability.’ The reporting of COI was satisfactory. CONCLUSIONS: For the recommendations on antithrombotic strategies, guidelines with high AGREE II scores still exist discrepancy on the timing and selection. Current guidance documents on the treatment vary in methodological rigor and recommendations are not always consistent. Ubiquity Press 2022-02-23 /pmc/articles/PMC8877875/ /pubmed/35342701 http://dx.doi.org/10.5334/gh.1104 Text en Copyright: © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Fan, Yongqiang
Zhang, Gaoxing
Zhang, Zhengzhipeng
Zhang, Shaozhao
Liu, Menghui
Lin, Yifen
Huang, Yiquan
Zhong, Xiangbin
Zhuang, Xiaodong
Liao, Xinxue
Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title_full Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title_fullStr Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title_full_unstemmed Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title_short Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
title_sort critical appraisal of guidelines for antithrombotic therapy in atrial fibrillation post-percutaneous coronary intervention
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877875/
https://www.ncbi.nlm.nih.gov/pubmed/35342701
http://dx.doi.org/10.5334/gh.1104
work_keys_str_mv AT fanyongqiang criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT zhanggaoxing criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT zhangzhengzhipeng criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT zhangshaozhao criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT liumenghui criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT linyifen criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT huangyiquan criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT zhongxiangbin criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT zhuangxiaodong criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention
AT liaoxinxue criticalappraisalofguidelinesforantithrombotictherapyinatrialfibrillationpostpercutaneouscoronaryintervention